$TERN

Merck cut its Terns Pharmaceuticals offer to $53/share from $61 following disappointing TERN-701 trial data, with a competing bidder also withdrawing its offer.

Merck stock fell 3.12% Tuesday despite announcing a $53-per-share acquisition of Terns Pharmaceuticals, pressured by broader market decline and healthcare sector weakness.

Merck acquires Terns Pharmaceutical for $6.7B to expand cancer pipeline with oral BCR-ABL1 inhibitor, targeting $70B commercial opportunity by mid-2030s.

Merck partners with Infinimmune for next-gen antibody drugs, gaining exclusive rights to candidates from AI-powered platform with up to $838M in potential milestone payments.

Merck agrees to acquire Terns Pharmaceuticals for $6.7B to strengthen pipeline before Keytruda's 2028 patent expiry, but analysts suggest competing bids may emerge.

Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.

Merck pursues $6B acquisition of Terns Pharma to strengthen oncology pipeline as Keytruda faces patent expiration amid broader $320B industry revenue cliff.

Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.

First Turn Management invests $35M in clinical-stage biotech Terns Pharmaceuticals, acquiring 4.03% stake. Stock surged 826% year-over-year on cancer drug trial progress.